These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 16721451)

  • 41. Advances in cervical cancer screening and human papillomavirus vaccines.
    Feeley C
    J Br Menopause Soc; 2006 Mar; 12(1):19-23. PubMed ID: 16513018
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Grounds for the inclusion of vaccination against cervical cancer within the National Immunisation Programme].
    de Kok IM; Habbema JD; Mourits MJ; Coebergh JW; van Leeuwen FE
    Ned Tijdschr Geneeskd; 2008 Nov; 152(48):2639-40; author reply 2640-1. PubMed ID: 19105259
    [No Abstract]   [Full Text] [Related]  

  • 43. Human papillomavirus vaccine, teen sex and politics.
    Olatunbosun O
    J Fam Plann Reprod Health Care; 2006 Apr; 32(2):74. PubMed ID: 16824294
    [No Abstract]   [Full Text] [Related]  

  • 44. Vaccinating adolescents and young women against cancer of the cervix.
    Hilgers RD; Wyatt SW
    J Ky Med Assoc; 2007 May; 105(5):215-6. PubMed ID: 17566465
    [No Abstract]   [Full Text] [Related]  

  • 45. Cervical cancer control in the era of HPV vaccination and novel biomarkers.
    Wentzensen N; Klug SJ
    Pathobiology; 2009; 76(2):82-9. PubMed ID: 19367128
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Human papillomavirus, cervical cancer prevention, and more.
    Lowy D
    Vaccine; 2008 Aug; 26 Suppl 10():iii-iv. PubMed ID: 18847562
    [No Abstract]   [Full Text] [Related]  

  • 47. Current status of human papillomavirus vaccines.
    Ma B; Roden R; Wu TC
    J Formos Med Assoc; 2010 Jul; 109(7):481-3. PubMed ID: 20677402
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Importance of High-Risk Human Papillomavirus Types Other Than 16 and 18 in Cervical Neoplasia.
    Robadi IA; Pharaon M; Ducatman BS
    Arch Pathol Lab Med; 2018 Jun; 142(6):693-695. PubMed ID: 29848032
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Public health. High hopes and dilemmas for a cervical cancer vaccine.
    Cohen J
    Science; 2005 Apr; 308(5722):618-21. PubMed ID: 15860602
    [No Abstract]   [Full Text] [Related]  

  • 50. Papillomavirus vaccine types 16 and 18: new drug. Cervical cancer: just another vaccine.
    Prescrire Int; 2008 Jun; 17(95):103-4. PubMed ID: 18623911
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions.
    Serrano B; de Sanjosé S; Tous S; Quiros B; Muñoz N; Bosch X; Alemany L
    Eur J Cancer; 2015 Sep; 51(13):1732-41. PubMed ID: 26121913
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A human papillomavirus type 16 vaccine.
    Tammela JE; Lele S; Odunsi K
    N Engl J Med; 2003 Apr; 348(14):1402-5; author reply 1402-5. PubMed ID: 12678018
    [No Abstract]   [Full Text] [Related]  

  • 53. Vaccine against papilloma virus: a review of the clinical studies.
    Gabutti G
    J Prev Med Hyg; 2009 Jun; 50(2):79-89. PubMed ID: 20099437
    [No Abstract]   [Full Text] [Related]  

  • 54. [Preventive vaccines against papillomavirus and cervix cancer will soon enter clinical practice].
    Lehtinen M; Malm C; Apter D; Heikkilä R; Heino P; Rimpilä K; Zilliacus R; Paavonen J
    Lakartidningen; 2003 Oct; 100(43):3408-12. PubMed ID: 14626768
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Should the antipapillomavirus vaccination after the age of 25 be advised?].
    Simon P; Poppe W
    J Gynecol Obstet Biol Reprod (Paris); 2008 Dec; 37(8):748-52. PubMed ID: 18752907
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
    Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
    BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.
    Rambout L; Hopkins L; Hutton B; Fergusson D
    CMAJ; 2007 Aug; 177(5):469-79. PubMed ID: 17671238
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Declining rates of cervical intraepithelial neoplasia in British Columbia, Canada: An ecological analysis on the effects of the school-based human papillomavirus vaccination program.
    Donken R; van Niekerk D; Hamm J; Spinelli JJ; Smith L; Sadarangani M; Albert A; Money D; Dobson S; Miller D; Lee M; Mitchell-Foster S; Krajden M; Naus M; Ogilvie G
    Int J Cancer; 2021 Jul; 149(1):191-199. PubMed ID: 33586169
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HPV testing in cervical screening.
    Cuzick J
    Pharmacoepidemiol Drug Saf; 2001; 10(1):33-6. PubMed ID: 11417064
    [No Abstract]   [Full Text] [Related]  

  • 60. Origin and immunoescape of uterine cervical cancer.
    Van Hede D; Langers I; Delvenne P; Jacobs N
    Presse Med; 2014 Dec; 43(12 Pt 2):e413-21. PubMed ID: 25448124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.